Lentinan exerts synergistic apoptotic effects with paclitaxel in A549 cells via activating ROS-TXNIP-NLRP3 inflammasome

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 8, 2015, Pages 1949-1955

  Liu, Wei ^a   Gu, Jun ^a   Qi, Jun ^a   Zeng, Xiao Ning ^b   Ji, Juan ^a   Chen, Zheng Zhen ^a   Sun, Xiu Lan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ROS; TXNIP; Lentinan; NLRP3; Paclitaxel

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE 3; INFLAMMASOME; INTERLEUKIN 1BETA; LENTINAN; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PACLITAXEL; REACTIVE OXYGEN METABOLITE; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; CRYOPYRIN; MAP3K5 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN; PROTEIN BINDING; TXNIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MTT ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TIME-DEPENDENT INHIBITION; WESTERN BLOTTING; BIOLOGICAL MODEL; CELL PROLIFERATION; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; PHOSPHORYLATION; TIME FACTOR; TUMOR CELL LINE;

APOPTOSIS; CARRIER PROTEINS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INFLAMMASOMES; LENTINAN; MAP KINASE KINASE KINASE 5; MODELS, BIOLOGICAL; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 84938206788     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12570     Document Type: Article

References (26)

1. Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol. 2014; 8: 1132-9.
2. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006; 580: 2903-9.
3. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002; 3: 755-66.
4. Gaitanos TN, Buey RM, Diaz JF, et al. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res. 2004; 64: 5063-7.
5. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471: 110-4.
6. Riedel RF, Porrello A, Pontzer E, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther. 2008; 7: 3141-9.
7. Wang Y, Cabral F. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta. 2005; 1744: 245-55.
8. Gupta ML Jr, Bode CJ, Georg GI, et al. Understanding tubulin-Taxol interactions: mutations that impart Taxol binding to yeast tubulin. Proc Natl Acad Sci USA. 2003; 100: 6394-7.
9. Foland TB, Dentler WL, Suprenant KA, et al. Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae. Yeast. 2005; 22: 971-8.
10. Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 2007; 120: 2078-85.
11. Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013; 13: 681-8.
12. Oba K, Kobayashi M, Matsui T, et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009; 29: 2739-45.
13. Moradali MF, Mostafavi H, Ghods S, et al. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol. 2007; 7: 701-24.
14. Ren L, Perera C, Hemar Y. Antitumor activity of mushroom polysaccharides: a review. Food Funct. 2012; 3: 1118-30.
15. Lee HH, Lee JS, Cho JY, et al. Structural characteristics of immunostimulating polysaccharides from lentinus edodes. J Microbiol Biotechnol. 2009; 19: 455-61.
16. Makropoulou M, Aligiannis N, Gonou-Zagou Z, et al. Antioxidant and cytotoxic activity of the wild edible mushroom Gomphus clavatus. J Med Food. 2012; 15: 216-21.
17. Noguchi T, Takeda K, Matsuzawa A, et al. Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem. 2005; 280: 37033-40.
18. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005; 38: 1543-52.
19. Lillig CH, Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal. 2007; 9: 25-47.
20. Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2013; 18: 1165-207.
21. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010; 11: 136-40.
22. Dolado I, Swat A, Ajenjo N, et al. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007; 11: 191-205.
23. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410: 37-40.
24. Matsuo Y, Yodoi J. Extracellular thioredoxin: a therapeutic tool to combat inflammation. Cytokine Growth Factor Rev. 2013; 24: 345-53.
25. Tobiume K, Saitoh M, Ichijo H. Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol. 2002; 191: 95-104.
26. Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta. 2008; 1780: 1325-36.